Adult chemo protocols beat pediatric ones for young AML patients. A retrospective study from Memorial Sloan Kettering found that adolescent and young adult (AYA) patients with acute myeloid leukemia (AML) treated with adult protocols had a 5-year overall survival rate of 77.9%, compared to just 56.7% with pediatric protocols — despite similar remission rates. The findings call for dedicated, AYA-focused treatment guidelines.
Adult AML protocols deliver a major survival edge for young patients
A new retrospective study challenges the long-held assumption that more intensive chemotherapy is better for younger leukemia patients. Researchers at Memorial Sloan Kettering Cancer Center analyzed 81 patients aged 14–29 diagnosed with acute myeloid leukemia (AML) between 2010 and 2025, comparing outcomes between adult and pediatric treatment protocols.
The results were striking: while both protocols achieved similar remission rates (~79% composite complete response), the adult protocol — centered on a single induction cycle of cytarabine plus daunorubicin (7+3) — significantly outperformed the more intensive pediatric regimen on survival. The survival advantage held across different risk categories and even among patients who went on to receive stem cell transplants.
By the Numbers
Why it matters: AYA patients with AML fall into a treatment gray zone — too old for some pediatric trials, too young to be lumped in with older adults. This study makes a compelling case that less-intensive, adult-style regimens may actually serve this group better, and underscores the urgent need for harmonized, AYA-specific treatment protocols.
